Repositioning Candidate Details

Candidate ID: R0411
Source ID: DB01116
Source Type: approved; investigational
Compound Type: small molecule
Compound Name: Trimethaphan
Synonyms: Thimethaphan; Trimetaphan; Trimetaphanum
Molecular Formula: C22H25N2OS
SMILES: O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1
Structure:
DrugBank Description: A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.
CAS Number: 7187-66-8
Molecular Weight: 365.512
DrugBank Indication: For the controlled reduction of blood pressure during surgery and in the treatment of hypertensive emergencies.
DrugBank Pharmacology: Trimethaphan is indicated for production of controlled hypotension during surgery to reduce bleeding into the surgical field and also for rapid reduction of blood pressure in the treatment of hypertensive emergencies, especially in patients with acute dissecting aneurysm, and in the emergency treatment of pulmonary edema in patients with pulmonary hypertension associated with systemic hypertension.
DrugBank MoA: Trimethaphan is a ganglionic blocking agent prevents stimulation of postsynaptic receptors by competing with acetylcholine for these receptor sites. Additional effects may include direct peripheral vasodilation and release of histamine. Trimethaphan's hypotensive effect is due to reduction in sympathetic tone and vasodilation, and is primarily postural.
Targets: Neuronal acetylcholine receptor subunit alpha-10 antagonist
Inclusion Criteria: Therapeutic strategy associated